Archive for 'Cell therapy'
Cardio3 BioSciences named Trends-Tendances Business Tour 2013 Most Innovative Company for Brabant Walloon
Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) has been named winner of the Trends-Tendances Business Tour 2013 Award in the “Innovation” category for the Brabant Walloon region. The Business Tour showcases three companies in each province in the country in [...]
Sirris has been using additive manufacturing technologies, known as “3D printing” to consumers, for nearly 25 years. Today, this research centre located in Gosselies (a hot-spot for health biotechnologies in Wallonia, Belgium) reaches another level and [...]
As the foundation for the new Walloon Cell Therapy Platform* begins to set in Gosselies, Belgium an exciting new development for Wallonia gets underway. The platform, unique in this sector, will provide Wallonia with a new [...]
Latest news from Mont-Saint-Guibert, Belgium – Cardio3 BioSciences SA has recently announced that it is considering raising new funds through an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris. This is an update to the [...]
Cardio3 BioSciences’ publishes Phase II trial results for stem cell therapy treatment in the JACC and increases its equity by €19 million.
Two exciting new announcements have recently been made by Belgian-based biotechnology company Cardio3 BioSciences(Mont-Saint Guibert, Wallonia). In early April the company announced the publication of Phase II trial results for stem cell therapy C-Cure® in the [...]
Updating on the February 15th post, some exciting new developments have recently occurred that further strengthen Bone Therapeutics’ cell product manufacturing capabilities. Following a successful Series D fundraising round, Bone Therapeutics, alongside the Walloon Region and private [...]
Bone Therapeutics completes a €7.7 Million Series D Fundraising round to further advance ongoing PREOB® Phase III clinical trials
Following the approval of the pivotal phase III osteonecrosis trial of PREOB® last November (posted Nov. 9, 2012), Bone Therapeutics has just completed a €7.7 million Series D fundraising round. Of the raised funds, €6.1 million were [...]
Cédric Blanpain receives Liliane Bettencourt Prize for his outstanding quality of international publications!
Adding to his achievements (see article posted July 13th, 2012) and his award for stem cell research, Cédric Blanpain, professor at the ULB, WELBIO IRIBHM investigator and Faculty of Medicine of the ULB, has been announced [...]
Prestigious European Albert Renold Award granted to Professor Decio L. Eizirik of the Universite Libre de Bruxelles (ULB).
Dr. Decio L. Eizirik, Laboratory Director and Professor at the Medical Faculty, Université Libre de Bruxelles (ULB), since 2002, has been selected for the 2012 Albert Renold Prize by the European Association for the Study of [...]
Bone Therapeutics gets approval for pivotal phase III osteonecrosis trial in Europe and treats first patients with their Advanced Therapy Medicinal Product PREOB®
After receiving clearance from the competent authorities in Europe for its phase III pivotal osteonecrosis* trial with their second generation Advanced Therapy Medicinal Product (ATMP), PREOB®, bone regenerative medicine company Bone Therapeutics recently announced that their [...]